Vineet Laboratories Limited
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
What Vineet files
- Others52
- Important44
- Board Meeting14
- Updates8
- QIP/Rights/Pref.2
- Insider Trade2
Vineet Laboratories has allotted 99,87,258 new equity shares at Rs.30 each, including a Rs.20 premium, as part of its Rights Issue. This move increases the company's total issued, subscribed, and paid-up equity shares to 1,92,06,266. Consequently, the paid-up share capital has risen from Rs.9.22 Cr to Rs.19.21 Cr. This capital...
Vineet Laboratories' Rights Issue Committee has extended the timeline for its ongoing Rights Issue to benefit investors. The last date for On Market Renunciation is now January 27, 2026, and the Issue Closing Date has been revised to January 30, 2026. This adjustment gives investors more time to participate. Consequently,...
Vineet Laboratories has arranged for Rights Entitlements (REs) to be credited to eligible shareholders' demat accounts for the upcoming Rights Issue. The ISIN for these REs is INE505Y20010, a key procedural step before the issue opens.
The company's Rights Issue Committee has approved the terms for a Rights Issue of 99,87,258 fully paid-up Equity Shares, aiming to raise Rs. 29.96 Cr. Each share is priced at Rs. 30 (Rs. 10 face value + Rs. 20 premium). Shareholders on record as of December 23, 2025, are eligible...
Vineet Laboratories' Rights Issue Committee meeting has been adjourned to December 17. The committee requires more time to finalize key aspects of the proposed Rights Issue, including the Issue Price, Entitlement Ratio, and the issue's opening and closing dates. These crucial decisions are contingent on receiving necessary preliminary approval. This...